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Aims: Glucagon like peptide 1 (GLP-1) analogues and dipeptidyl peptidase IV (DPP-4) inhibitors reduce
atherosclerosis progression in type 2 diabetes mellitus (T2DM) patients and are associated with
morphological and compositional characteristics of stable plaque phenotype. GLP-1 promotes the secretion
of adiponectin which exerts anti-inﬂammatory effects through the adaptor protein PH domain and leucine
zipper containing 1 (APPL1). The potential role of APPL1 expression in the evolution of atherosclerotic plaque
in TDM2 patients has not previously evaluated.
Methods: The effect of incretin therapy in the regulation of adiponectin/APPL1 signaling was evaluated both
on carotid plaques of asymptomatic diabetic (n = 71) and non-diabetic patients (n = 52), and through in
vitro experiments on endothelial cell (EC).
Results: Atherosclerotic plaques of T2DM patients showed lower adiponectin and APPL1 levels compared with
non-diabetic patients, along with higher oxidative stress, tumor necrosis factor-α (TNF-α), vimentin, and
matrix metalloproteinase-9 (MMP-9) levels. Among T2DM subjects, current incretin-users presented higher
APPL1 and adiponectin content compared with never incretin-users. Similarly, in vitro observations on
endothelial cells co-treated with high-glucose (25 mM) and GLP-1 (100 nM) showed a greater APPL1 protein
expression compared with high-glucose treatment alone.
Conclusions: Our ﬁndings suggest a potential role of adiponectin/APPL1 signaling in mediating the effect of
incretin in the prevention of atherosclerosis progression or plaque vulnerability in T2DM.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular disease (CVD) based on atherosclerosis is themajor
cause of mortality in subjects with type 2 diabetes mellitus (T2DM)
(Grundy et al., 1999). T2DM is well known to accelerate the clinical
course of atherosclerosis, an inﬂammatory disease of the arterial wall,
in which leukocytes and oxidized lipoproteins accumulate, leading to
the formation of atherosclerotic plaques (Creager, Luscher, Cosentino,
& Beckman, 2003). The conversion of a stable plaque to a vulnerable
plaque involves many processes, including inﬂammation, cellular
breakdown, expansion of the cellular component, thinning of the
ﬁbrous cap, formation of a large lipid core, and intraplaqueve no conﬂict of interest.
39 81 5665303.
Barbieri).
Inc. This is an open access article uhemorrhage. Inﬂammatory events secondary to diabetes play a key
role in the plaque erosion and ﬁssuring (Menegazzo et al., 2015).
Several new pharmacological compounds have been developed to
treat T2DM patients including glucagon like peptide 1 (GLP-1)
analogues and dipeptidyl peptidase IV (DPP-4) inhibitors (Kim &
Egan, 2008). Recent studies suggest that treatment with DPP-4
inhibitors and GLP-1 analogues has a protective effect on CVD (Ussher
& Drucker, 2012). In particular, DPP-4 inhibitors have been recently
shown to reduce atherosclerosis progression in T2DM patient
probably through the reduction of over daily inﬂammation and
oxidative stress (Barbieri et al., 2013). Furthermore, more recent
studies demonstrated the incretin treatment to be associated with
morphological and compositional characteristics of a potential stable
plaque phenotype (Balestrieri et al., 2015; Burgmaier et al., 2013). In
particular, it has been demonstrated that GLP-1 reduces plaque
inﬂammation and increase phenotypic characteristics of plaquender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
296 M. Barbieri et al. / Journal of Diabetes and Its Complications 31 (2017) 295–303stability in a murine model of atherosclerosis (Balestrieri et al., 2015;
Burgmaier et al., 2013; Gaspari, Welungoda, Widdop, Simpson, &
Dear, 2013). The mechanisms underlying the decreased risk of
developing cardiovascular disease are still poorly understood.
Interestingly, treatment with exendin-4, an agonist of the GLP-1
receptor, promotes increases of adiponectin expression and plasma
levels in high fat-fed rats (Li et al., 2008). Furthermore, administration
of liraglutide prevented hypoadiponectinemia-induced increases in
plasma insulin, free fatty acids, triglycerides and total cholesterol in
high fat diet APOE−/− mice (Li et al., 2011). Liraglutide also
attenuated hypoadiponectinemia-induced deterioration in peripheral
and hepatic insulin sensitivity and alterations in key regulatory factors
implicated in glucose and lipid metabolism (Li et al., 2011). In
Japanese T2DM patients, serum adiponectin levels increased after
three-month treatment with sitagliptin without change of body
weight (Nonaka et al., 2008). Furthermore, treatment of T2DM
patients with sitagliptin reversed vascular endothelial dysfunction,
as evidenced by the increase in the ﬂow mediated dilation (FMD)
(Kubota et al., 2012). The changes in the FMD signiﬁcantly correlated
with those of the plasma adiponectin.
Numerous studies have shown that low plasma adiponectin
concentrations are associated with increased plaque vulnerability in
patients with coronary artery disease (Sawada et al., 2010). The
anti-atherosclerotic effects of adiponectin have been demonstrated at
several stages of plaque development, ranging from endothelial
dysfunction and plaque initiation to plaque progression and rupture
(Sawada et al., 2010).
Adiponectin exerts its effects through two membrane receptors,
ADIPOR1 and ADIPOR2 (Nonaka et al., 2008). Adaptor protein PH
domain and leucine zipper containing 1 (APPL1) and adaptor
protein PH domain and leucine zipper containing 2 (APPL2) are
the ﬁrst identiﬁed adaptor proteins that interact directly with
adiponectin receptors (Deepa & Dong, 2009). They are highly
expressed in insulin target tissues, including skeletal muscle, liver
and adipose tissue andmediate adiponectin effects on metabolism via
binding to N terminus of adiponectin receptors (Deepa & Dong, 2009).
Adiponectin signaling through APPL1 is necessary to exert its
anti-inﬂammatory and cytoprotective effects on EC (Mao et al.,
2006; Wang et al., 2011).
Furthermore, APPL1 also acts as a mediator of other pathways by
interacting directly with membrane receptors or signaling proteins,
playing critical roles in cell proliferation, apoptosis, cell survival,
endosomal trafﬁcking, and chromatin remodeling (Han, 2012) and
represents an important key regulator of insulin signaling and
secretion (Ryu et al., 2014). To this regard, it has been shown that
knockout (KO) of APPL1 in mice reduced insulin and adiponectin
signaling and led to systemic insulin resistance. Indeed, both insulin
resistance (IR) and hyperglycemia play important roles in athero-
genesis promoting, both early stages of lesion formation and clinically
relevant advanced plaque progression and contributing to atheroma
plaque vulnerability which is partly due to augmented inﬂammatory
pathway expression within the plaque (Martínez-Hervás et al., 2014).
No evidence exist about a potential role of APPL1 expression in the
evolution of atherosclerotic plaque in T2DM patients. We hypothe-
sized that diabetes may affect the anti-inﬂammatory and cytoprotec-
tive effects of APPL1 on EC favoring the instability of atherosclerotic
plaques phenotype and that an incretin-induced increase in adipo-
nectin/APPL1 signaling may contribute to the stabilization of plaque,
thus, preventing atherosclerosis progression in T2DM patients. Thus,
this study was designed to identify differences in adiponectin, APPL1
expression, as well as in inﬂammatory inﬁltration, in carotid plaques
of asymptomatic diabetic and non-diabetic patients. Indeed, the
effects of incretin therapy on APPL-1 expression in carotid plaques of
diabetic patients, were also investigated. Furthermore, the incretin
effect on APPL-1 expression was also evaluated by a set of in-vitro
experiments on endothelial cell (EC).2. Research design and methods
Patients were recruited from the outpatient Department of
Cardiology and Cardiovascular Surgery of the Cardarelli Hospital,
Naples, Italy, from January 2009 to December 2014. Among them 71
type 2 diabetic and 52 non-diabetic patients (non-diabetic group)
with asymptomatic carotid stenosis (according to North American
Symptomatic Carotid Endarterectomy Trial classiﬁcation), enlisted to
undergo carotid endarterectomy for extracranial high-grade (N70%)
internal carotid artery stenosis (Young et al., 1996) were selected.
Asymptomatic patients underwent a baseline clinical examination,
medical history, and computed tomography or MRI. Carotid sonog-
raphy was performed on a single ultrasound machine (Aloka 5500).
Diabetes was diagnosed according to American Diabetes Association
criteria (Moghissi et al., 2009). T2DM patients answered a speciﬁc
questionnaire about medicines used for diabetes treatment, the date
of the beginning and end of treatment, route of administration, and
duration of use. Questionnaire was developed for producing data
about patients medication use for treating diabetes. Structured
closed-ended questionnaire was prepared in Italian language and
was administered by trained experienced clinicians. The collected
data were reviewed and checked for completeness and consistency by
diabetologist. Questions were simple, clear and easy to understand.
Questionnaire was completed by all the patients enrolled and the
collected data were compared with information from clinical chart or
general practice doctor's prescription. T2DM patients who never used
incretin, such as GLP-1 agonists and DPP-4 inhibitors, were classiﬁed
as “never incretin-users.” T2DM patients who had already used GLP-1
agonists or DPP-4 inhibitors were classiﬁed as “current incretin-
users.” Among the 71 T2DM patients enrolled, 38 were current
incretin-users, and 33 were never incretin-users. Information on
duration of treatment was available for all current incretin-users. A
duration of incretin treatment was 38 ± 6 months. All patients had
no clinical or laboratory evidence of heart failure, previous stroke,
valvular defects, malignant neoplasms, or secondary causes of
hypertension nor neurologic symptoms or cerebral lesions as assessed
by computed tomography. During the observational period, dietary
counseling was added to the previous therapy. The study was
approved by the ethics committee of Cardarelli Hospital, and
informed written consent was obtained for each patient. The study
has been carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2008.
2.1. Laboratory analysis
After an overnight fast, plasma glucose, HbA1c, serum lipids were
measured by enzymatic assays. Adiponectin plasma levels were
measured with Orgenium Laboratories' human ELISA test. For
estimation of circulating intact GLP-1, plasma immunologic active
form of GLP-1 (7-36)was determined using a speciﬁc ELISA kit (Active
GLP-1 7-36, Epitope). Blood samples were collected in ice-cooled
blood collection system for plasma GLP-1 preservation tubes (BD
P700) and immediately, were centrifuged at 2500 rpm for 10 minutes
in refrigerated centrifuge. Samples were stored at −80 °C. In
particular GLP-1 levels (Active GLP-1 7-36, Epitope) were measured
after an overnight fast and after breakfast. Standardized breakfast
contained 419 kcal (57% carbohydrate, 17% protein, and 26% fat).
After breakfast, blood samples for measurement of GLP-1 were
obtained every 30 min along 2 h. The mean of the four GLP-1
evaluations was deﬁned as post-prandial GLP-1 value.
2.2. Plaque phenotype
In order to characterize plaque phenotype, inﬂammatory inﬁltra-
tion, matrix metalloproteinases (MMPs), TNF-α, nitrotyrosine, and
vimentin content have been evaluated.
297M. Barbieri et al. / Journal of Diabetes and Its Complications 31 (2017) 295–303Stable plaques are rich in VSMC and collagen with few inﬂamma-
tory cells whereas unstable high risk plaques that are prone to rupture
contain few VSMCs, more macrophages and little collagen (Adiguzel,
Ahmad, Franco, & Bendeck, 2009; Dhume & Agrawal, 2003; Spagnoli,
Bonanno, Sangiorgi, & Mauriello, 2007). The stability of atheroscle-
rotic plaques depends on the balance between the matrix formation
and degradation of extracellular matrix (ECM) (Molloy et al., 2004;
Rao, Kansal, Stoupa, & Agrawal, 2014). The activated macrophages
and T-lymphocytes present in atherosclerotic plaques secrete matrix
metalloproteinases (MMPs) that degrade extracellular matrix pro-
teins, and weaken the ﬁbrous cap, leading to myocardial infarction
and stroke. Indeed, VSMCs may exhibit a differential protein content
as a result of atherosclerosis development. Vimentin is a structural
component of microtubules and intermediate ﬁlaments. Strong
vimentin staining has been detected in the active areas of inﬂamma-
tion at the edge of necrotic and inﬂammatory areas and at the plaque
shoulder. The non-lesion side of the artery showed minimal
immunoreactivity. The cells involved in the atherosclerotic plaques
secrete inﬂammatory cytokines such as tumor necrosis factor-alpha
(TNF-α), interferon-gamma (IFN-γ) and interleukin-12 (IL-12)
(Tedgui & Mallat, 2006). Among these, TNF-α, a powerful pleiotropic
cytokine with multiple cellular functions, plays a role in the
inﬂammation, initiation, development, susceptibility, severity, and
response to treatment, etc. Interestingly the pro-inﬂammatory
cytokine tumor necrosis factor alpha (TNF-α) can trigger secretion
of vimentin (Rao, Rai, Stoupa, Subramanian, & Agrawal, 2016).
Activation of inﬂammatory cells is also associated with an increase
in oxidative stress potentially promoting plaque rupture. Beckman et
al. ﬁrst detected protein nitrotyrosine formation in early subintimal
fatty streaks and in foamy macrophages within lesions of human
coronary arteries in 1994 (Beckmann et al., 1994). In vitro studies
demonstrated that nitrotyrosine is a highly speciﬁc marker of LDL
oxidized. Nitration of LDL is thought to interfere with cholesterol
transport and trigger the release of TNF-α, which can amplify the
inﬂammatory response (Smythe, Skinner, Bruckdorfer, Haskard, &
Landis, 2003).
2.3. Atherectomy specimens
Specimens taken during the carotid endoarterectomy were cut
perpendicular to the long axis into two halves. The ﬁrst half was
frozen in liquid nitrogen for the following ELISA analysis. A portion of
the other half specimen was immediately immersion-ﬁxed in 10%
buffered formalin. Sections were serially cut at 5 μm, mounted on
lysine-coated slides, and stainedwith hematoxylin and eosin andwith
the trichrome method. Carotid artery specimens were analyzed by
light microscopy.
2.4. Immunohistochemistry
After the surgical procedure, samples were immediately frozen in
isopentane and cooled in liquid nitrogen. Similar regions of the plaque
were analyzed (Fig. A.1). Serial sections were incubated with speciﬁc
antibodies against adiponectin (1:50, Santa Cruz), APPL1 (1:500,
Santa Cruz), nitrotyrosine (1:50 Santa Cruz), CD3 (1:25, Dako), matrix
metalloproteinase-9 (MMP-9) (1:50, Santa Cruz), tumor necrosis
factor-α (TNF-α) (1:20 R&D), CD68 (1:50, Santa Cruz), and vimentin
(1:400, Dako). The sections were processed and colored using the
automatic immunostainer “Bench-Mark 7600”; the positivity of
sections is given by the binding of a chromogen, diaminobenzidine,
to the site of the antigen–antibody reaction which develops a brown
coloration. Quantitative immunohistochemistry analysis was per-
formed by quantitative 24-bit color image analysis system (IM500;
Leica Microsystem AG) and ImageJ software. Results are expressed as
percentage of positivity.2.5. Biochemical assays
Plaque content of MMP9, TNF-α, and nitrotyrosine was evaluated
by ELISA assays. Speciﬁc kits were used to quantify MMP-9 (Santa
Cruz), TNF-α (R&D Systems), and nitrotyrosine (Imgenex) levels
according to the calibration curves provided by manufacture's
protocol. Total protein were determined by Lowry assay (Lowry,
Rosebrough, Farr, & Randall, 1951). Each determination was repeated
at least three times.2.6. Endothelial cell culture and treatments
Human aortic ECs (HAECs) (Lonza Cologne, Walkersville,
MD, USA) were cultured with EGM-2MV BulletKit (Lonza)
supplemented with 5% FBS, 0.6% HEPES, at 37 °C in a 5% CO2
humidiﬁed atmosphere, and used between passage 4 and 7.
Short-term exposure to high-glucose (25 mM) was carried out in
the presence or absence of GLP-1 receptor agonist (Exenatide, Byetta)
(100 nM) in complete culture media for 3 days. To this end, ECs were
cultured in six-well plates (Costar, Corning, NY, USA) at 70–80%
conﬂuence. GLP-1 receptor agonist was added 30 min before starting
the high-glucose treatment and left in the culture media throughout
the high-glucose treatment. Control cells were cultured for 3 days
under basal conditions.2.7. Confocal laser-scanning microscopy
Immunoﬂuorescence detection by confocal laser-scanning micro-
scope analysis (Zeiss LSM 700) was performed on deparafﬁnized
atherosclerotic plaque sections from patients enrolled and on in
vitro-cultured EC, as previously described (Balestrieri et al., 2015).
Samples were incubated overnight at 37 °C with antibodies against
APPL1 (1:500) (Abcam, Cambridge, UK), von Willebrand factor
(1:500) (Abcam, Cambridge, UK), and vimentin (1:1000) (Sigma, St.
Louis, MO, USA). Secondary antibodies were Alexaﬂuor 633 (1:1000)
or Alexaﬂuor 488 (1:1000) (Invitrogen, Life Technologies Italia,
Monza, Italy). The ﬂuorescence intensity was quantiﬁed with ImageJ
software and expressed as arbitrary ﬂuorescence units (AFU).2.8. Western blot analysis
Protein extracts of plaque tissues and EC were prepared as
previously described (Balestrieri et al., 2015). Brieﬂy, tissues
(400 mg) were washed twice in PBS and cut into small pieces.
Protein extraction was performed by adding 800 μl of 2D lysis buffer
(ratio weight/volume 1:2) (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM
Tris–HCl, pH 8.8). Samples were homogenized using a tissue
homogenizer (Precellys 24, Bertin Technologies, Bertin Pharma,
Montigny-le-Bretonneux, France). Tubes containing homogenized
tissue were placed on a tube shaker for 30 min and then centrifuged
at 800 ×g for 10 min at 4 °C to collect the supernatant. An aliquot of
the supernatant was used for total protein determination by the
Lowry method (Lowry et al., 1951). Protein extracts (15 μg) were
separated by 7% SDS-polyacrylamide gel electrophoresis and trans-
ferred onto nitrocellulose membranes by Trans-Blot Turbo Transfer
System (BioRad). Membranes were incubated overnight at 4 °C with
antibodies against APPL1 (1:3000) (Abcam, Cambridge, UK cod
59592) followed by incubation with secondary antibody. Membranes
were normalized with a polyclonal antibody against γ-tubulin protein
(1:1000) (GTU-88) (Sigma, St. Louis, MO, USA). Band detection was
performed by the enhanced chemiluminescence kit (ECL, Amersham,
Aylesbury, UK) and semiquantitative densitometry by Scan LKB
(Amersham Pharmacia).
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All variables are presented as means ± standard deviation (SD).
The in vitro data shownweremean values of at least four independent
experiments and expressed as mean ± SD. In order to investigate
differences between study groups, sample size was estimated by
GPOWER software. The resulting sample size, estimated according to a
global effect size of 0.30 with type I error of 0.05 and a power of 80%
was 111 patients.
Analysis of variance (ANOVA) with Scheffe's test was used for
analyze differences among different groups. Statistical signiﬁcance
was set at a level of P b 0.05. Pearson product-moment correlations
were calculated to test associations among variables. Statistical
analyses were performed using the SPSS statistical package.
3. Results
Clinical characteristics of the study population are presented in
Table 1. Percentage of carotid diameter reduction, risk factors, and
concomitant non-hypoglycemic therapy did not differ among the
groups. In T2DMpatients, mean plasma glucose, BMI and HbA1c levels
did not differ between never and current incretin-users. However,Table 1
Clinical characteristic of study population (n = 123).
Patients characteristics Non diabetic (N = 52)
Age, years 73.7 ± 4.5
Sex (female/male) 28/24
BMI (kg/m2) 28.5 ± 1.7
Systolic blood pressure (mm Hg) 129 ± 12.8
Diastolic blood pressure (mm Hg) 77 ± 5.7
Total cholesterol (mmol/l) 5.53 ± 1.04
HDL cholesterol (mmol/l) 1.39 ± 0.42
Triglycerides (mmol/l) 1.85 ± 0.23
HbA1C (%) 5.2 ± 0.5⁎†
Blood glucose (mmol/l) 4.9 ± 0.32⁎†
Insulin (μU/ml) 11.22 ± 2.24⁎†
Basal GLP-1 (pmol/l) 10.3 ± 1.26⁎†
Postprandial GLP-1 (pmol/l) 27.1 ± 3.05⁎†
Fasting adiponectin (μg/ml) 9.65 ± 1.5⁎†
CRP (mg/dl) 1.66 ± 0.17⁎†
Coronary artery disease 26 (50)
Hypertension 22 (42)
Hypercholesterolemia 18 (38)
Cigarette smoking 17 (32)
Drug use (%)
Aspirin 42 (80)
Warfarin 4 (8)
β-Blocker 16 (30)
Calcium-channel blocker 6 (12)
Statin 35 (68)
ACE inhibitor 25 (48)
Diuretic agent 17 (32)
AT-2 antagonist 21 (40)
Insulin –
Sulfonylureas –
Metformin –
PPAR-γ agonists –
Acarbose –
GLP-1agonists –
DPP-4 inhibitors –
Plaque characteristics
Macrophage-rich areas, % 6.1 ± 1.4⁎†
T-cells per mm2 section area 16.4 ± 6.4⁎†
Vimentin, % 8.9 ± 2.3⁎†
MMP-9, μg/mg 4.2 ± 1.5⁎†
Nitrotyrosine, nmol/pg 1.8 ± 0.6⁎†
TNF-α, pg/mg 24.4 ± 4.18⁎†
Data are presented as mean ± SD, or number (%). CRP= C-reactive protein; IHD= ischemic
high-density lipoprotein; peroxisome proliferator–activated receptor = PPAR-γ; GLP-1 = g
* P b 0.05 compared with never current user group.
† P b 0.05 compared with current user group.fasting plasma adiponectin, basal and post-prandial GLP-1 levels were
higher in current compared to never incretin-users (P b 0.01). Both
basal and post prandial plasma GLP-1 correlated positively with
plasma adiponectin levels (respectively r = 0.52; p b 0.01 and r =
0.65; p b 0.01) and negatively with plaque TNF-α (respectively
r = − 0.60; p b 0.01 and r = −0.78; p b 0.01), MMP9 (respectively
r = −0.57; p b 0.01 and r = −0.82; p b 0.01) and nitrotyrosine
(respectively r = − 0.57; p b 0.01 and r = −0.78; p b 0.01) content.
3.1. Plaque composition
Compared with non-diabetic patients, both diabetic incretin-users
(n = 38) and never incretin-users (n = 33) had a signiﬁcantly
greater portion of plaque area occupied by macrophages and T-cells
(Table 1 and Fig. 1). Among diabetic patients, current incretin-users
group had a signiﬁcant smaller portion of plaque area occupied by
macrophages (P b 0.01) and T-cells (P b 0.01) compared with the
never incretin-user group (Table 1 and Fig. 1). Both immunohisto-
chemistry and ELISA revealed markedly higher staining and levels of
TNF-α in both current (p b 0.05) and never incretin-users (p b 0.05)
compared with non-diabetic lesions. Among diabetic patients,
staining and levels of TNF-α were signiﬁcantly more abundant inNever incretin-users (N = 33) Current incretin-users (N = 38)
71.3 ± 5.8 72.2 ± 4.5
19/14 24/14
30.6 ± 1.9 29.5 ± 2.4
129 ± 21.3 128 ± 13.3
77.3 ± 6.3 79.4 ± 6.6
5.71 ± 1.17 5.68 ± 0.95
1.26 ± 0.71 1.27 ± 0.24
2 ± 0.27 1.86 ± 0.30
8.3 ± 0.6 7.9 ± 0.8
8.9 ± 1.14 8.8 ± 1.16
14.03 ± 1.04 13.31 ± 1.67
7.9 ± 1.77 9 ± 0.82⁎
16.4 ± 2.66 25 ± 3.09⁎
5.68 ± 1.26 8.78 ± 0.73⁎
2.06 ± 0.30 2.04 ± 0.11
19 (58) 23 (62)
16 (48) 19 (50)
14 (43) 17 (44)
10 (30) 10 (26)
29 (90) 36 (94)
2 (6) 2 (6)
8 (25) 11 (28)
5 (16) 6 (16)
25 (77) 29 (76)
20 (62) 24 (64)
9 (28) 10 (26)
12 (36) 13 (34)
5 (16) 4 (12)
5 (16) 5 (14)
24 (73) 23 (62)
– –
5 (15) 7 (18)
– 5 (14)
– 33 (88)
24.8 ± 2.6 17.1 ± 1.9⁎
72.5 ± 14.9 29.1 ± 7.3⁎
28.3 ± 2.03 19.2 ± 1.9⁎
17.9 ± 1.2 8.9 ± 1.1⁎
6.5 ± 0.8 3.4 ± 0.7⁎
94.4 ± 6.02 61.4 ± 6.6⁎
heart disease; BMI= bodymass index; ACE= angiotensin-converting enzyme; HDL=
lucagon-like peptide-1; DPP-4 = dipeptidyl-peptidase-4.
Fig. 1. Inﬂammation in atherosclerotic plaques. Representative images of immunochemical analysis of macrophages (CD68) (X400), lymphocytes (CD3) (X400) and TNF-α (X400) in
control, current incretin-user, and never incretin-user asymptomatic plaques. Similar regions of plaque are shown. These results are typical of control, current incretin-user, and
never incretin-user asymptomatic plaques.
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incretin-users group (P b 0.001) (Table 1 and Fig. 1). MMP-9 levels
were more abundant in diabetics current (P b 0.01) and never
incretin (P b 0.01) than in non-diabetic lesions. In particular,
MMP-9 levels were more abundant in lesions from diabetic never
incretin-users than lesions from the current incretin-user group. As
far as vimentin, higher content was found in plaques of both current
(P b 0.01) and never incretin-users (P b 0.01) compared with
non-diabetic patients (Table 1 and Fig. 2). Content of vimentin of
plaques from never incretin-users was higher than lesions from the
current incretin-user group (P b 0.001) (Fig. 2). Higher nitrotyrosine
levels were found in diabetic than in non-diabetic plaques
(P b 0.001vs. both current and never incretin-users). Among diabetic
plaques, nitrotyrosine levels were signiﬁcantly higher in never
incretin-users than in current incretin-users (P b 0.01) (Fig. 2).3.2. APPL1 protein levels in atherosclerotic plaques from diabetic and
non-diabetic patients
Both immunohistochemistry (Fig. 2) and confocal laser-scanning
microscopy analyses (Fig. 3, panel A and B) revealed that levels of
APPL1 were consistently lower in plaques from diabetic patients
compared to plaques from non-diabetic patients and, speciﬁcally, in
plaques from diabetic never incretin-users (P b 0.01). APPL1 immu-
noﬂuorescence expression levels were found consistently lower in
plaques from diabetic never incretin-users compared to non-diabetic
patients (20.05 ± 1.8 vs. 31.05 ± 2.01 arbitrary ﬂuorescence units
(AFU)) (P b 0.05). Levels of APPL1 in plaques from current
incretin-users were signiﬁcantly higher than those observed in
never incretin-users (26.58 ± 1.5 vs. 20.05 ± 1.8 AFU) (P b 0.05)(Fig. 3 panel A). Likewise, Western blot analysis of APPL1 protein
levels in atherosclerotic plaques from non-diabetic and diabetic
patients (current and never incretin-users) showed a similar trend
(Fig. 3 panel B). Indeed, never incretin-users APPL1 arbitrary units
(AU) were 48.2% lower than non-diabetic patients (P b 0.01) whereas
APPL1 levels of current incretin-users were 21% lower than
non-diabetic patients (P b 0.05). Moreover, immunoﬂuorescence
co-expression of APPL1 and von Willebrand factor suggested that
APPL1 is expressed at endothelial levels and conﬁrmed the lower
APPL1 expression level in plaques from diabetic never incretin-users
compared to current incretin-users and non-diabetic patients (Fig.
A.2). Finally, adiponectin levels have been found to be lower in
plaques from diabetic patients compared to plaques from
non-diabetic patients and, speciﬁcally, in plaques from diabetic
never incretin-users (P b 0.01) (Fig. 2).3.3. High-glucose (hGluc) and GLP-1 receptor agonist effect on APPL1
expression in EC
The effect of high-glucose (hGluc) concentration and GLP-1
receptor agonist was evaluated in vitro on cultured EC. Confocal
laser scanning microscopy revealed that short-term exposure to
hGluc down-regulates APPL1 protein after 18 h (P b 0.05) and 24 h
(P b 0.01) of exposure (Fig. 4). Interestingly, in EC treated
hGluc + GLP-1, the APPL1 protein levels were near to control values.
Similar results were obtained when the expression levels of APPL1
were evaluated byWestern blot analysis (Fig. A.3). Indeed, short-term
exposure to hGluc down-regulates APPL1 protein after 18 h (0.86 ±
0.03 arbitrary units vs. 1.067 ± 0.014 in control cells) (P b 0.05) and
24 h (0.75 ± 0.02 arbitrary vs. 0.51 ± 0.01 in control cells) (P b 0.01)
Fig. 2. Atherosclerotic plaque phenotypes. Representative images of immunochemical analysis of APPL1 (X400), adiponectin (X400), MMP-9 (X400), vimentin (X400), and
nitrotyrosine (X400) in control, current incretin-user, and never incretin-user asymptomatic plaques. Similar regions of plaque are shown. These results are typical of control,
current incretin-user, and never-incretin user asymptomatic plaques.
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APPL1 protein levels were signiﬁcantly higher that observed in cells
treated with hGluc alone (P b 0.05 vs. hGluc).
4. Discussion
This study provides the ﬁrst evidence of the relationship between
the APPL1 signaling pathway and the inﬂammatory process at
atherosclerotic plaque levels in T2DM patients. Indeed, results
demonstrated that atherosclerotic plaques of diabetic patients have
lower adiponectin and APPL1 levels, compared with atherosclerotic
plaques of non-diabetics. Moreover, levels of adiponectin and APPL1
in the atherosclerotic plaques of diabetic patients were associated
with higher oxidative stress, pro-inﬂammatory cytokine TNF-α,
and MMP-9 levels, as well as higher interstitial vimentin content.Interestingly, among diabetic subjects, those current incretin-users
showed higher APPL1 and adiponectin content compared with never
incretin-users.
APPL1 and APPL2 are the ﬁrst identiﬁed adaptor proteins
that directly interact with adiponectin receptors (Deepa & Dong,
2009). They are both highly expressed in insulin target tissues,
including skeletal muscle, liver and adipose tissue and mediate
adiponectin signaling and its effects on metabolism (Deepa & Dong,
2009). APPL1 positively mediates adiponectin signaling in cells and its
interaction with ADIPOR1 is inhibited by overexpression of APPL2
(Wang et al., 2009).
Low plasma adiponectin concentration has been found associated
with increased plaque vulnerability in patients with coronary artery
disease (Sawada et al., 2010). The anti-atherosclerotic effects of
adiponectin have been demonstrated at several stages in plaque
Fig. 3. APPL1 expression in atherosclerotic plaques of diabetic and non-diabetic patients. (A) Representative confocal images of APPL1 (red) and vimentin (green). Bar graph of APPL1
arbitrary ﬂuorescence units (AFU). (B) Western blot analysis of APPL1 protein levels in atherosclerotic plaque homogenates from non-diabetic patients (L1, L3), diabetic
never-incretin-users (L2), and diabetic current incretin-users (L4). Insets, representative images of Western blot analysis. Data are mean ± SD with (A) ⁎⁎P b 0.01 vs. non-diabetic,
⁎P b 0.05 vs. non-diabetic, §P b 0.05 vs. never incretin-users, (B) ǂP b 0.01 vs. non-diabetic, ⁎⁎P b 0.05 vs. non-diabetic.
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initiation to plaque progression and rupture (Sawada et al., 2010;
Zhu, Cheng, Vanhoutte, Lam, & Xu, 2008). Adiponectin exerts its
vasculoprotective effects through its direct actions in the vascular
system, such as increasing endothelial nitric oxide (NO) production,
inhibiting EC activation and endothelium–leucocyte interaction,
enhancing phagocytosis, and suppressing macrophage activation,
macrophage-to-foam cell transformation and platelet aggregation
(Zhu et al., 2008). In addition, adiponectin reduces neointima
formation through an oligomerization-dependent inhibition of
smooth muscle proliferation. Adiponectin signaling through APPL1
exerts anti-inﬂammatory and cytoprotective effects on EC (Cheng
et al., 2007), linking adiponectin receptors and the downstream
signaling events leading to increased NO production (Cheng et al.,
2007; Zhu et al., 2008). T2DM is well known to lead to increased
vulnerability for plaque disruption (Creager et al., 2003) and to be
associated with reduced adiponectin plasma levels (Kadowaki et al.,
2006). To date, no studies have established the direct involvement of
APPL1 in the atherogenic process and in evolution versus instability of
atherosclerotic plaque, in T2DM patients. In this study, the lower
APPL1 content in atherosclerotic plaque was associated with higher
oxidative stress, pro-inﬂammatory cytokine TNF-α, nitrotyrosine, and
MMP-9 levels along with higher interstitial vimentin content, thus
suggesting that the beneﬁcial anti-atherosclerotic effect of adiponec-
tin might be mediated by APPL1 signaling. Previous studies have
reported that APPL1 is an important mediator of insulin secretion and
actions in the liver (Cheng et al., 2009), skeletal muscles (Cleasbyet al., 2011), adipocytes (Saito, Jones, Huang, Czech, & Pilch, 2007),
and endothelium (Wang et al., 2011). Increasing evidence demon-
strates that APPL1 is a positive regulator of insulin sensitivity by acting
as a common relay of both adiponectin and insulin signaling
pathways. The expression of APPL1 is dramatically decreased in
pancreatic islets and vascular endothelium in several rodent models
of diabetes and obesity (Cheng et al., 2012). Furthermore, recent
ﬁndings linking APPL1mutations to familial forms of diabetes reafﬁrm
the critical role of APPL1 in glucose homeostasis (Prudente et al.,
2015). Accordingly, in our study atherosclerotic plaques from diabetic
subjects have signiﬁcantly lower content of APPL1 compared with
atherosclerotic plaques from non diabetic subjects. Interestingly, in
vitro experiments on cultured EC, demonstrated that short-term
exposure to high-glucose down-regulates APPL1 protein, suggesting
that, a detrimental vicious circle in which hyperglycemia alters APPL1
signaling may occur. This, in turn, could affect the anti-inﬂammatory
and cytoprotective effects of APPL1 on EC favoring the instability of
the atherosclerotic plaques.
More intriguing, among diabetes subjects, current incretin-users
showed higher levels of adiponectin and APPL1 and reduced plaque
inﬂammation compared to never incretin-users. It has been previ-
ously demonstrated that incretin therapy reduces atherosclerosis
progression in patient with T2DM, probably through the reduction of
over daily inﬂammation and oxidative stress (Barbieri et al., 2013;
Burgmaier et al., 2013; Kubota et al., 2012; Li et al., 2011). A more
recent study have demonstrated that incretin treatment is associated
with morphological and compositional characteristics of a potential
Fig. 4. Confocal laser scanning microscope analysis of APPL1 expression in endothelial cells after short-term exposure to high-glucose and GLP-1. Representative confocal images of
APPL1 (red) and vimentin (green) of control (CTR) cells and cells treated for 18 h and 24 h with hGluc, GLP-1 (GLP-1), and high-glucose in the presence of GLP-1 (hGluc + GLP-1).
Bar graph of APPL1 AFU. Data are mean ± SD (n = 6) with ⁎P b 0.05 vs. CTR, ⁎⁎P b 0.01 vs. CTR, and §P b 0.05 vs. hGluc.
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studies have demonstrated that incretin therapy promotes adiponec-
tin secretion (Li et al., 2008), increases its circulating levels (Quan
et al., 2014) and attenuates hypoadiponectinemia-induced alterations
in key regulatory factors implicated in glucose and lipid metabolism
(Li et al., 2011), our results are the ﬁrst demonstration of a potential
role of APPL1 signaling in mediating the effect of incretin in the
prevention of atherosclerosis progression or plaque vulnerability in
T2DM. Such hypothesis is strengthened by the in vitro results
indicating that EC co-treated with high-glucose and GLP-1 receptor
agonist show higher APPL1 protein levels compared to high-glucose-
treated EC and ﬁrstly suggesting a potential role of APPL1 as a target
for GLP-1 signaling. However, before drawing a ﬁrm conclusion,
further in vitro and/or in vitro studies are needed to deﬁne whether
blocking APPL1 could prevent the effects of incretin on high-glucose
damages. Potential limitations in our study are the relatively low
number of current incretin users which precluded the inclusion of
GLP1-R agonist users and DPPIV users as separate groups, the lack of
in vitro experiment linking incretin therapy with adiponectin levels,
and the need of replicating our ﬁnding in an independent larger
population group.
5. Conclusions
In conclusion, the evidence of the involvement of APPL1 signaling
in the inﬂammatory process occurring in the atherosclerotic plaques
of T2DM patients, and in the complex framework of the signaling
pathways altered by hyperglycemia in EC opens new perspectives indeﬁning the mechanism of action of incretin as an effective strategy
for preventing atherosclerosis progression in T2DM patients.
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